Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial

IMPORTANCE: Ramucirumab, a human IgG 1 antibody against vascular endothelial growth factor receptor 2, has been shown to improve progression-free survival and overall survival in patients with advanced gastric cancer in the second-line setting. OBJECTIVE: To compare progression-free survival for S-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Takaki, Muro, Kei, Shitara, Kohei, Oh, Do-Youn, Kang, Yoon-Koo, Chung, Hyun Cheol, Kudo, Toshihiro, Chin, Keisho, Kadowaki, Shigenori, Hamamoto, Yasuo, Hironaka, Shuichi, Yoshida, Kazuhiro, Yen, Chia-Jui, Omuro, Yasushi, Bai, Li-Yuan, Maeda, Kaijiro, Ozeki, Akichika, Yoshikawa, Reigetsu, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681552/
https://www.ncbi.nlm.nih.gov/pubmed/31373648
http://dx.doi.org/10.1001/jamanetworkopen.2019.8243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681552/
https://www.ncbi.nlm.nih.gov/pubmed/31373648
http://dx.doi.org/10.1001/jamanetworkopen.2019.8243

Ejemplares similares